Project Grant F30CA294670
- This $388,256 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at the Medical University of South Carolina to investigate the biologic rationale of fallopian tube removal to prevent uterine serous carcinoma. The key objectives include: Testing murine surgical methods to remove the ovary and fallopian tube and assess impact on reducing cancer cell identification within the uterus. Utilizing lentiviral cell...
- This $744,575 project grant was awarded on May 16, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The grant is funding research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to define the genomic and biologic impact of LINE-1 activity in fallopian tube epithelial cells and its role in the development of high-grade serous ovarian cancer (HGSOC). The research involves...
- This Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research to advance the understanding of ovarian cancer and develop a high-performance liquid biopsy for ovarian cancer screening. The $162,486 award was granted to The Johns Hopkins University to pursue three specific aims: 1) Expand a novel bioinformatics approach to study repeat elements in cell-free DNA, 2) Characterize the repeat element landscape in ovarian cancer, and...
- The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...
- This federal Project Grant award in the amount of $155,605 was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, to conduct research on the association between contraception use and ovarian/breast cancers through metabolic profiling. The overarching goal of this 1-year project is to comprehensively quantify changes in metabolites and pathways associated with oral contraception...
- This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $154,000 to The University of Kentucky Research Foundation to investigate the role of long non-coding RNAs (lncRNAs) in the ovulatory process. The research aims to identify the top 5 most highly LH/HCG-regulated lncRNAs and characterize their function in the ovary, particularly the role of the lncRNA GM12648 in regulating genes...
- This Project Grant award, totaling $419,014, was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant supports research to investigate the role of the transcription factor SOX9 in regulating the ovulatory process and corpus luteum development in the human ovary. The research aims to provide critical insights into the mechanisms underlying...
- This federal Project Grant award of $412,429.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research at the Mayo Clinic to investigate novel approaches for treating high-grade serous ovarian cancer (HGSOC). The research aims to evaluate how the nuclear translocation of cathepsin L (NCTSL) can sensitize CCNE1-driven HGSOC tumors to combination therapies involving DNA-damaging agents and PARP inhibitors. Key objectives include...
- This $474,946 Project Grant awarded on February 1, 2025 by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to develop a novel, multipurpose device for female-initiated, non-hormonal contraception. The key products to be delivered under this grant include: Design and prototyping of a dual-compartment vaginal device that enables women to administer a bioresponsive polymer fiber mat...
- The National Institute of Child Health and Human Development (NICHD) awarded a $613,556 Project Grant to Orygyn Medical Devices, LLC under the Child Health and Human Development Extramural Research program (CFDA 93.865) for the development of a novel Tubal Selective Delivery System (TSDS). The TSDS is designed to safely and conveniently evaluate fallopian tube patency in an office setting as part of the infertility workup, without the need for referral to a specialist or exposure to ionizing...
THE EFFECTS OF OVULATION ON FALLOPIAN TUBE-DERIVED TUMORIGENESIS USING MICROFLUIDIC PREDICT-MOS PLATFORM - PROJECT SUMMARY/ABSTRACT HIGH GRADE SEROUS OVARIAN CANCER (HGSOC) IS THE MOST PREVALENT AND LETHAL HISTOTYPE OF OVARIAN CANCER. THE FALLOPIAN TUBE IS THE PRIMARY ORIGIN OF MOST HGSOCS, SUPPORTED BY EVIDENCE FROM MOLECULAR ANALYSIS AND CLINICALLY DEMONSTRATED BY THE PROTECTIVE EFFECT OF SALPINGECTOMY. OVULATION IS A MAJOR RISK FACTOR FOR OVARIAN CANCER. CURRENTLY, THE ONLY MEANS FOR PREVENTION ARE THROUGH THE REDUCTION OF LIFETIME OVULATORY EVENTS, SUCH AS THROUGH THE USE HORMONAL BIRTH CONTROL OR SURGICAL REMOVAL OF THE FALLOPIAN TUBES AND OVARIES. THE COMPLEXITY IN UNDERSTANDING THE DYNAMIC INTERPLAY BETWEEN OVARIAN SECRETIONS AND FALLOPIAN TUBE EPITHELIUM (FTE) IS COMPOUNDED BY THE DEEP-SEATED ABDOMINAL LOCATION AND THE ELUSIVE DISPERSION OF FLUIDS SECRETED BY THE OVARY INTO THE PERITONEAL SPACE. THEREFORE, THE MOLECULAR MECHANISMS THAT DRIVE THE INITIATION OF OVARIAN CANCER IN THE FALLOPIAN TUBE IN RESPONSE TO OVULATION ARE POORLY UNDERSTOOD. TO ADDRESS THESE CHALLENGES, OUR COLLABORATIVE TEAM HAS DEVELOPED A PHYSIOLOGICALLY ACCURATE MENSTRUAL CYCLE MODEL USING THE PREDICT MULTI-ORGAN SYSTEM (MOS), A MICROFLUIDIC (ORGAN-ON-CHIP) DEVICE THAT ENABLES US TO RECAPITULATE THE PROCESS OF OVULATION AND CAPTURE THE ENTIRETY OF OVARIAN SECRETIONS. ADDITIONALLY, OUR LAB ENGINEERED PRENEOPLASTIC MURINE OVIDUCTAL EPITHELIAL (MOE) CELL MODELS (EQUIVALENT TO THE HUMAN FALLOPIAN TUBE) THAT EXPRESS THE MOST COMMONLY AND EARLIEST IDENTIFIED ABERRATIONS IN HGSOC: PAX2 LOSS AND P53 MUTATION (R2723H). UTILIZING OVULATION SECRETIONS CAPTURED ON THE PLATFORM, WE OBSERVED AN UPREGULATION OF DNA DAMAGE RESPONSE TRANSCRIPTS IN THE FALLOPIAN TUBE MODELS, FOLLOWED BY AN INCREASE IN PROLIFERATION CAUSED BY SECRETIONS FROM THE LUTEAL PHASE IN OUR PAX2 DEFICIENT CELLS. THESE FINDINGS ARE SIGNIFICANT, AS THEY DEMONSTRATE THAT OVARIAN SECRETIONS INDUCE DNA DAMAGE AND PROLIFERATION IN THE FTE. OUR PROPOSED AIMS ENCOMPASS UNDERSTANDING THE PATHWAYS ASSOCIATED WITH DNA DAMAGE, OXIDATIVE STRESS, AND CELL MIGRATION CAUSED BY OVULATION AS WELL AS UNCOVERING THE MOLECULAR PATHWAYS THAT DRIVE FTE PROLIFERATION IN THE LUTEAL PHASE. ADDITIONALLY, WE WILL INVESTIGATE THE IN VITRO EFFICACY OF A COX2 INHIBITOR TO ACT AS A POTENTIAL CHEMOPREVENTATIVE AGENT AND TO MITIGATE THE DAMAGING EFFECTS OF OVULATION. WITH INCREASING INTEREST IN NON-HORMONAL BIRTH CONTROL METHODS, OUR PROPOSAL REPRESENTS A STEP TOWARDS INVESTIGATING A NON-HORMONAL STRATEGY FOR PREVENTION. THROUGH THE EXPERIMENTS OUTLINED IN THIS PROPOSAL, WE AIM TO IDENTIFY THE EARLY MECHANISMS INVOLVED IN HGSOC INITIATION BY STUDYING PHASE-DEPENDENT CHANGES CAUSED BY SECRETIONS FROM THE OVARY. THE RESEARCH PROJECT AND STRATEGIES WILL FACILITATE MY TRAINING AS A PHARMD/PHD STUDENT GIVEN THEIR FOCUS ON UNCOVERING MECHANISMS AND TREATMENTS FOR HGSOC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $46.7k | 6/16/25 |